Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Highlights of Merck’s Q4 2023 financial results
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite a modest increase in revenues.
Fourth-quarter worldwide sales increased 6% year-over-year to $14.6 billion, mainly reflecting the sustained growth across oncology and vaccines.
The company reported a net loss of $1.23 billion or $0.48 per share for the December quarter, compared to a profit of $3.02 billion or $1.18 per share in the prior-year period. On an adjusted basis, it was earnings of $0.03 per share in Q4, down 98% from the fourth quarter of 2022.
“As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team,” said Merck’s CEO Robert Davis.
Prior Performance
Most Popular
Netflix (NFLX) stands tall in a heavily competitive streaming landscape
Shares of Netflix, Inc. (NASDAQ: NFLX) were down over 2% on Friday. The stock has gained 27% over the past three months. The streaming giant continues to hold its ground
Starbucks (SBUX): A look at the challenges that continue to beleaguer the coffee giant
Shares of Starbucks Corporation (NASDAQ: SBUX) rose 2% on Thursday. The stock has dropped 9% over the past month. The company has faced its fair share of challenges during fiscal
Broadcom (AVGO) thrives on growing AI business. Is the stock a buy?
Broadcom, Inc. (NASDAQ: AVGO), a leading provider of semiconductor solutions for wired and wireless communications, recently impressed the market with upbeat financial outlook highlighting strong prospects for its AI business
